Recent studies have demonstrated that the resistance to treatment with Cisplatin and Adriamycin is caused by the overexpression of BARD1 and BRCA1 in tamoxifen-resistant breast carcinoma cells [125]. Here, BRCA1 is linked to breast carcinoma.